Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009
October 26 2009 - 8:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that Company
management will provide a corporate update and review of the third
quarter 2009 results via webcast and conference call on Tuesday,
November 3, 2009, at 4:30 p.m. ET.
To access the live audio webcast or the subsequent archived
recording, visit the “Investors - Presentations and Events” section
of the Company’s website at www.allos.com. Alternatively, callers
may participate in the conference call by dialing 1-877-941-8610
(domestic) or 480-629-9819 (international). Participants should
reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available
approximately two hours after the completion of the call through
Friday, November 13, 2009. To access the replay, callers should
dial 1-800-406-7325 (domestic) or 303-590-3030 (international) and
use passcode 4169927#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYNTM (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The 2009 third quarter results press release and conference call
will contain forward-looking statements that involve significant
risks and uncertainties, including those contained in the "Risk
Factors" section of the company's Form 10-Q for the quarter ended
June 30, 2009 and in the company's other periodic reports and
filings with the Securities and Exchange Commission. Allos is
providing the information contained in the press release and
conference call as of the date of the release and does not
undertake any obligation to update any forward-looking statements
as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024